Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study
Date
2008Author
Briassoulis, E. ChFountzilas, George
Bamias, A. T.
Dimopoulos, M. A.
Xiros, N.
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Samantas, E.
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Makatsoris, T.
Mylonakis, N.
Papakostas, P.
Skarlos, Dimosthenis V.
Varthalitis, I.
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Source
Cancer chemotherapy and pharmacologyVolume
62Issue
2Pages
277-284Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas. Methods: This was a multicenter phase-II trial. Protocol treatment consisted of oxaliplatin 80 mg/m2 followed by irinotecan 160 mg/m2 administered every 3 weeks. The primary end points were response rate and toxicity, and secondary end points were time to progression and survival. Results: Forty-seven patients with liver, bone or multiple visceral metastases entered into the trial and received a median 6 chemotherapy cycles (1-11). The regimen was very well tolerated with one febrile neutropenia case and six cases with diarrhea grade 3 (16%). In intent-to-treat analysis the tumor response rate was 13% (95% CI = 4.8-25.7%) and 12 patients (27%, 95%CI 13.9-40.4%) had at least 4 months' duration of disease stabilization. The median time to progression was 2.7 months and the median survival was 9.5 months, with 40% of patients alive at 1 year. Conclusions: The IROX regimen demonstrated similar efficacy and a favorable toxicity profile compared to other more toxic chemotherapy combinations in patients with poor-prognosis CUP. © 2007 Springer-Verlag.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
Fountzilas, George; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A. K.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, Panagiotis; Karanikiotis, C.; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Samantas, E.; Varthalitis, I.; Pavlidis, Nicholas; Pectasides, Dimitrios; Dimopoulos, M. A. (2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...
-
Article
Late toxicity in survivors from adolescent cancers
Pentheroudakis, George; Pavlidis, Nicholas (2007)Nowadays three quarters of adolescents with cancer are cured but half of them experience a late toxic effect of antineoplastic therapy that interferes with their physical and psychosocial health. This review recapitulates ...
-
Article
Evidence that NPHS2-R229Q predisposes to proteinuria and renal failure in familial hematuria
Voskarides, Konstantinos; Arsali, Maria; Athanasiou, Yiannis; Elia, Avraam; Pierides, Alkis M.; Constantinou-Deltas, Constantinos D. (2012)Background Familial hematuria (FH) is associated with at least two pathological entities: Thin basement membrane nephropathy (TBMN), caused by heterozygous COL4A3/ COL4A4 mutations, and C3 nephropathy caused by CFHR5 ...